Venclyxto and MabThera combo gets approval in Europe for CLL
The approval allows more patients to be treated with Venclyxto in the second-line setting while giving healthcare providers the ability to prescribe the drug to a larger population
The National Medical Products Administration (NMPA) of China has approved Keymed Biosciences’ new drug application granting marketing approval for Stapokibart to treat adults with moderate-to-severe atopic dermatitis.